Cannabis sativa research trends, challenges, and new-age perspectives Tajammul Hussain, Ganga Jeena, Thanet Pitakbut, Nikolay Vasilev, and Oliver Kayser iScience, Cell Press, 2021,24, 103391, 1-13. Doi : 10.1016/j.isci.2021.103391 SUMMARY Cannabis sativa L. has been one of the oldest medicinal plants cultivated for 10,000 years for several agricultural and industrial applications. However, the plant became controversial owing to some psychoactive components that have adverse effects on human health. In this review, we analyzed the trends in cannabis research for the past two centuries. We discussed the historical transitions of cannabis from the category of herbal medicine to an illicit drug and back to a medicinal product post-legalization. [...]
Lire la suiteMedical cannabis for severe treatment resistant epilepsy in children : a case-series of 10 patients Rayyan Zafar, Anne Schlag, Lawrence Phillips, David J Nutt BMJ Paediatrics Open, 2021, 5, e001234. doi : 10.1136/bmjpo-2021-001234 ABSTRACT Objectives : To report the findings of a case-series of 10 children suffering with intractable epilepsies in the UK to determine the feasibility for using whole-plant cannabis medicines to treat seizures in children. Setting : This study was conducted retrospectively through collecting clinical data from caretakers and clinicians on study outcome variables. Participants were recruited through the MedCann Support and End our Pain charity groups which are patient representative groups that support children [...]
Lire la suiteThe Impact of Cannabidiol on Human Brain Function : A Systematic Review, Albert Batalla et al., 2021
The Impact of Cannabidiol on Human Brain Function : A Systematic Review Albert Batalla, Julian Bos, Amber Postma and Matthijs G. Bossong Frontiers in Pharmacology, January 2021 | Volume 11 | Article 618184, 1-15. doi : 10.3389/fphar.2020.618184 Background : Accumulating evidence suggests that the non-intoxicating cannabinoid compound cannabidiol (CBD) may have antipsychotic and anxiolytic properties, and thus may be a promising new agent in the treatment of psychotic and anxiety disorders. However, the neurobiological substrates underlying the potential therapeutic effects of CBD are still unclear. The aim of this systematic review is to provide a detailed and up-todate systematic literature overview of neuroimaging studies [...]
Lire la suiteEDITORIAL : Cannabinoids in psychiatry : they are here to stay Julia Jiyeon Woo, Emma van Reekum, Sagnik Bhattacharyya and Zainab Samaan The British Journal of Psychiatry, 2022, 1-3. doi : 10.1192/bjp.2021.216 Summary Cannabinoids are commonly perceived by the public as safe and effective for improving mental health, despite limited evidence to support their use. We discuss reasons why cannabinoids may be particularly compelling for our patients and provide strategies for how psychiatrists can counsel and educate patients on the evidence regarding cannabinoids. Keywords : Cannabis; drug interactions and side-effects; drugs of dependence disorders; marijuana; education and training. Vignette A young man sits in his psychiatrist’s office. After [...]
Lire la suiteCannabidiol as a Therapeutic Alternative for Post-traumatic Stress Disorder : From Bench Research to Confirmation in Human Trials Rafael M. Bitencourt and Reinaldo N. Takahashi Frontiers in Neuroscience, 2018, 12, 502, 1-10. Doi : 10.3389/fnins.2018.00502 Post-traumatic stress disorder (PTSD) is characterized by poor adaptation to a traumatic experience. This disorder affects approximately 10% of people at some point in life. Current pharmacological therapies for PTSD have been shown to be inefficient and produce considerable side effects. Since the discovery of the involvement of the endocannabinoid (eCB) system in emotional memory processing, pharmacological manipulation of eCB signaling has become a therapeutic possibility for the treatment of [...]
Lire la suiteIntegrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder Matthew N. Hill, Patrizia Campolongo, Rachel Yehuda and Sachin Pate Neuropsychopharmacology REVIEWS, 2018, 43, 80–102. doi : 10.1038/npp.2017.162 Exposure to stress is an undeniable, but in most cases surmountable, part of life. However, in certain individuals, exposure to severe or cumulative stressors can lead to an array of pathological conditions including posttraumatic stress disorder (PTSD), characterized by debilitating trauma-related intrusive thoughts, avoidance behaviors, hyperarousal, as well as depressed mood and anxiety. In the context of the rapidly changing political and legal landscape surrounding use of cannabis products in the USA, [...]
Lire la suiteCannabinoids, Pain, and Opioid Use Reduction : The Importance of Distilling and Disseminating Existing Data Kent E. HUTCHISON, Sarah L. HAGERTY, Jeffrey GALINKIN, Angela D. BRYAN, L. Cinnamon BIDWELL Cannabis and Cannabinoid Research, 2019, 4, (3), 158-164. Doi : 10.1089/can.2018.0052 Abstract The high prevalence of chronic pain conditions combined with an over-reliance on opioid prescriptions has resulted in an opioid epidemic and a desperate need for solutions. There is some debate about whether cannabis might play a role in addressing chronic pain conditions as well as the opioid epidemic. Recent surveys suggest that a large number of people are using cannabis as a treatment for [...]
Lire la suiteCannabidiol EPIDYOLEX 100 mg/ml, solution buvable Première évaluation COMMISSION DE LA TRANSPARENCE AVIS 13 MAI 2020 Haute Autorité de Santé, HAS - Direction de l'Evaluation Médicale, Economique et de Santé Publique Avis définitif L’essentiel Avis favorable au remboursement en association au clobazam dans le traitement des crises d’épilepsie associées au syndrome de Lennox-Gastaut (SLG) ou au syndrome de Dravet (SD), chez les patients de 2 ans et plus. Quel progrès ? Un progrès thérapeutique dans le traitement des crises d’épilepsie associées au syndrome de Lennox-Gastaut ou au syndrome de Dravet, chez les patients de 2 ans et plus. Quelle place dans la stratégie thérapeutique ? Crises d’épilepsie [...]
Lire la suiteCANNABIDIOL (CBD) : Critical Review Report, WHO, 2018 Expert Committee on Drug Dependence Fortieth Meeting Geneva, 4-7 June 2018 Contents Acknowledgements .................................................................................................................. 4 Summary................................................................................................................................... 5 1. Substance identification ........................................................................................................ 6 A. International Nonproprietary Name (INN) ............................................................................ 6 B. Chemical Abstract Service (CAS) Registry Number .............................................................. 6 C. Other Chemical Names .......................................................................................................... 6 D. Trade Names .......................................................................................................................... 6 E. Street Names........................................................................................................................... 6 F. Physical Appearance.............................................................................................................. 6 G. WHO Review History ............................................................................................................. 6 2. Chemistry ............................................................................................................................... 6 A. Chemical Name ...................................................................................................................... 6 B. Chemical Structure................................................................................................................. 7 C. Stereoisomers ......................................................................................................................... 7 D. Methods and Ease of Illicit Manufacturing............................................................................ 7 E. Chemical Properties............................................................................................................... 9 F. Identification and Analysis ..................................................................................................... 9 3. Ease of Convertibility Into Controlled Substances ............................................................ 10 4. General Pharmacology........................................................................................................ 11 A. Routes of administration and [...]
Lire la suiteMedical cannabis authorization and the risk of cardiovascular events : a longitudinal cohort study Arsene Zongo, Cerina Lee, Jason R. B. Dyck, Jihane El‑Mourad, Elaine Hyshka, John G. Hanlon and Dean T. Eurich BMC Cardiovascular Disorders, 2021, 21, 426 doi : 10.1186/s12872-021-02229-6 Abstract Background : Cannabis is increasingly used for therapeutic purpose. However, its safety profile is not well known. This study assessed the risk of cardiovascular-related emergency department (ED) visit and hospitalization in adult patients authorized to use medical cannabis in Ontario, Canada from 2014 to 2017. Methods : This is a longitudinal cohort study of patients who received medical cannabis authorization and followedup in [...]
Lire la suite